ACG Wealth Boosts Stake in Celgene Co. (NASDAQ:CELG)

Celgene logo ACG Wealth boosted its stake in Celgene Co. (NASDAQ:CELG) by 3.1% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 48,098 shares of the biopharmaceutical company’s stock after purchasing an additional 1,432 shares during the period. ACG Wealth’s holdings in Celgene were worth $4,538,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Janney Capital Management LLC lifted its holdings in Celgene by 2.9% in the fourth quarter. Janney Capital Management LLC now owns 4,219 shares of the biopharmaceutical company’s stock worth $270,000 after acquiring an additional 120 shares during the last quarter. Iberiabank Corp raised its holdings in shares of Celgene by 1.0% during the first quarter. Iberiabank Corp now owns 12,019 shares of the biopharmaceutical company’s stock valued at $1,134,000 after buying an additional 121 shares during the last quarter. Pitcairn Co. raised its holdings in shares of Celgene by 3.0% during the fourth quarter. Pitcairn Co. now owns 4,289 shares of the biopharmaceutical company’s stock valued at $275,000 after buying an additional 124 shares during the last quarter. Winthrop Advisory Group LLC raised its holdings in shares of Celgene by 4.1% during the fourth quarter. Winthrop Advisory Group LLC now owns 3,171 shares of the biopharmaceutical company’s stock valued at $203,000 after buying an additional 125 shares during the last quarter. Finally, Asset Dedication LLC raised its holdings in shares of Celgene by 35.5% during the first quarter. Asset Dedication LLC now owns 477 shares of the biopharmaceutical company’s stock valued at $44,000 after buying an additional 125 shares during the last quarter. Hedge funds and other institutional investors own 74.27% of the company’s stock.

Shares of CELG stock opened at $95.21 on Friday. Celgene Co. has a 1 year low of $58.59 and a 1 year high of $95.45. The company has a market cap of $67.27 billion, a PE ratio of 12.51, a P/E/G ratio of 0.43 and a beta of 1.68. The company has a current ratio of 2.78, a quick ratio of 2.66 and a debt-to-equity ratio of 2.42.

Celgene (NASDAQ:CELG) last announced its earnings results on Thursday, April 25th. The biopharmaceutical company reported $2.55 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $2.45 by $0.10. Celgene had a net margin of 30.10% and a return on equity of 106.69%. The company had revenue of $4.03 billion for the quarter, compared to analyst estimates of $4.01 billion. During the same period in the prior year, the business earned $2.05 earnings per share. Celgene’s quarterly revenue was up 13.8% on a year-over-year basis. Research analysts predict that Celgene Co. will post 9.85 EPS for the current year.

In other news, Director Ernest Mario bought 2,000 shares of the stock in a transaction on Tuesday, February 12th. The stock was purchased at an average price of $89.99 per share, with a total value of $179,980.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link . Also, Director James J. Loughlin sold 23,466 shares of the company’s stock in a transaction that occurred on Thursday, February 7th. The shares were sold at an average price of $87.29, for a total transaction of $2,048,347.14. Following the completion of the sale, the director now directly owns 62,102 shares of the company’s stock, valued at approximately $5,420,883.58. The disclosure for this sale can be found here . Corporate insiders own 0.39% of the company’s stock.

CELG has been the topic of a number of research analyst reports. Jefferies Financial Group lowered shares of Celgene from a “buy” rating to a “hold” rating and set a $95.00 price objective on the stock. in a research note on Friday, February 1st. ValuEngine upgraded shares of Celgene from a “strong sell” rating to a “sell” rating in a research report on Friday, January 4th. BidaskClub upgraded shares of Celgene from a “strong sell” rating to a “sell” rating in a research report on Friday, January 4th. William Blair reissued a “buy” rating on shares of Celgene in a research note on Thursday, February 28th. Finally, Wells Fargo & Co decreased their target price on shares of Celgene from $90.00 to $84.00 and set a “market perform” rating for the company in a research note on Thursday, January 3rd. One research analyst has rated the stock with a sell rating, eighteen have assigned a hold rating and eight have given a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average target price of $99.41.

About Celgene

Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers.

See Also: Calculating net profit and net profit margin ratio Institutional Ownership by Quarter for Celgene (NASDAQ:CELG) Receive News & Ratings for Celgene Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Celgene and related companies with MarketBeat.com’s FREE daily email newsletter .

Click Here to Continue...